27 März 2018 Jahr - FDA held a meeting of the Psychopharmacologic
Drugs Advisory Committee to discuss the new
drug application for lofexidine hydrochloride,
submitted by US WorldMeds, LLC, for mitigation
of symptoms associated with opioid withdrawal
and facilitation of completion of opioid
discontinuation treatment.
